Research progress in mechanisms of small bowel adenocarcinoma

doi:10.12092/j.issn.1009-2501.2018.02.018

Abstract

Abstract:

Small bowel adenocarcinoma (SBA) is a rare malignant tumor with poor prognosis and low overall survival. Researches of recent years have shown that the environmental factors and genetic factors play a role in the development of SBA. In addition, a variety of genetic mutations, DNA methylation, DNA mismatch repair, microsatellite instability and related signal pathways were activated abnormally involved in the occurrence and development of SBA. However, the pathogenesis of SBA is not completely clear and further research should be performed to provide theoretical basis and new ideas for the clinical diagnosis, treatment and prognosis of SBA.

Key words: small bowel adenocarcinoma, pathogenic factors, molecular mechanism

CLC Number:

R735.3+2

SONG Caixia, MA Qiang. Research progress in mechanisms of small bowel adenocarcinoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 211-216.

References

［1］Laforest A, Aparicio T, Zaanan A, et al. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma［J］.Eur J Cancer,2014,50(10): 1740-1746.
［2］Overman MJ, Hu CY, Kopetz S, et al. A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease ［J］. Ann Surg Oncol, 2012, 19(5):1439-1445.
［3］Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012［J］. CA Cancer J Clin, 2012, 62:10-29.
［4］Bennett CM, Coleman HG, Veal PG, et al. Lifestyle factors and small intestine adenocarcinoma risk: A systematic review and meta-analysis［J］.Cancer Epidemiol, 2015, 39(3):265-273.
［5］Shenoy S. Genetic risks and familial associations of small bowel carcinoma ［J］. World J Gastrointest Oncol, 2016, 8(6):509-519.
［6］Schrock AB, Devoe CE, Mcwilliams R, et al. Genomic profiling of small-bowel adenocarcinoma ［J］. JAMA Oncol, 2017, 3(11):1546-1553.
［7］Jun SY, Lee EJ, Kim MJ, et al. Lynch syndrome-related small intestinal adenocarcinomas ［J］. Oncotarget, 2017, 8(13): 21483-21500.
［8］Zhang YF, Mao XY, Zheng JC, et al. Small intestine adenocarcinoma associated with Peutz-Jeghers syndrome: a report of 5 cases and literature review ［J］. J Clin Oncol, 2014, 13(7): 337-340.
［9］Svrcek M, Piton G, Cosnes J, et al. Small bowel adenocarcinomas complicating Crohn's disease are associated with dysplasia: a pathological and molecular study ［J］. Inflamm Bowel Dis, 2014, 20(9):1584-1592.
［10］Aparicio T, Zaanan A, Svrcek M, et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment ［J］. Digest Liver Dis, 2014, 46(2): 97-104.
［11］Goh AM, Xue Y, Leushacke M, et al. Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice ［J］. Oncotarget, 2015, 6(20):17968-17980.
［12］Hsiao SJ, Remotti HE. Beta-catenin and p53 expression in ampullary and small intestinal adenocarcinoma ［J］. J Clin Oncol, 2013, 31(15): e14659.
［13］Chen L, Wu T, Pathology DO. Elevation of Notch1- and P53-immunoreactivity in small intestinal adenocarcinoma［J］. Chin J Histochem Cytochem, 2016, 2:130-135.
［14］ Pedersen LN, Krlev L, Teglbjrg PS, et al. Glutathione S -transferase genotype and p53 mutations in adenocarcinoma of the small intestine［J］. Scand J Gastroentero, 2003, 38(8):845-849.
［15］Gulhati P, Raghav K, Shroff RT, et al. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study［J］. Cancer, 2017, 123(6): 1011-1017.
［16］Freeman TJ, Smith JJ, Chen X, et al. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin［J］. Gastroenterol, 2012, 142(3): 562-571.
［17］郭文娟, 王爱英, 高春. 小肠腺癌组织的细胞凋亡及相关蛋白Bid和Bcl-xL的表达及意义［J］. 世界华人消化杂志, 2010, 18(11):1127-1133.
［18］Yang MC, Lin RW, Huang SB, et al. Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53 ［J］. Cell Cycle, 2016, 15(3):394-402.
［19］Jun SY, Kim M, Gu MJ, et al. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma［J］. Mod Pathol, 2016, 29(4): 402-415.
［20］李小燕, 卢可, 张志,等. E-cadherin在小肠腺癌、小肠腺瘤中的表达及其意义［J］. 安徽医药, 2014,(11):2112-2114.
［21］Lee HJ, Lee OJ, Jang KT, et al. Combined loss of E-cadherin and aberrant β-Catenin protein expression correlates with a poor prognosis for small intestinal adenocarcinomas［J］. Am J Clin Patholo, 2013, 139(2):167-176.
［22］Alvi MA, Mcart DG, Paul K, et al. Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility［J］. Oncotarget, 2015, 6(25):20863-20874.
［23］Overman MJ, Pozadzides J, Kopetz S, et al. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine ［J］. Brit J Cancer, 2010, 102(1):144-150.
［24］高峰, 王小云, 卢加杰,等. 小肠腺癌微卫星不稳定与hMLH1和hMSH2基因突变相关性分析［J］. 中华肿瘤防治杂志, 2014, 21(9):688-691.
［25］Zaaimi Y, Aparicio T, Laurentpuig P, et al. Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives ［J］. Clin Res Hepatol Gas, 2016, 40(2):154-160.
［26］Michel S, Kloor M, Singh S, et al. Coding microsatellite instability analysis in microsatellite unstable small intestinal adenocarcinomas identifies MARCKS as a common target of inactivation ［J］. Mol Carcinogen, 2010, 49(2):175-182.
［27］Kim KJ, Kim JY, Hong SM, et al. Loss of CADM4 expression is associated with poor prognosis in small intestinal adenocarcinomas［J］. Apmis, 2017, 125(5): 437-443.
［28］吴婧婧, 顾康生. 小肠腺癌患者中MMP-9、Ki-67、EGFR和VEGF的表达与临床特征及预后的相关性研究［J］. 安徽医科大学学报, 2013, 48(6):647-651.
［29］吴晓华, 张莘, 周文阔. 原发性小肠腺癌中 PTEN 蛋白及 PCNA 的表达及临床意义［J］. 河北医药, 2014(3):330-332.
［30］Suzuki H, Hirata Y, Suzuki N, et al. Characterization of a new small bowel adenocarcinoma cell line and screening of anti-cancer drug against small bowel adenocarcinoma ［J］. Am J Pathol, 2015, 185(2): 550-562.
［31］Zhang H, Zhang C. Expressions of filam in A and protein kinase B in small bowel adenocarcinoma and their significance［J］.J Transl Med, 2016,1:14-18.
［32］Hare LM, Phesse TJ, Waring PM, et al. Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice［J］. Biochem J, 2014, 458(2):251-258.
［33］Janku F, Tsimberidou AM, Garridolaguna I, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors ［J］. Mol Cancer Ther, 2011, 10(3):558.
［34］ Pedersen K, Smyrk TC, Harrington S, et al. Programmed death-ligand 1 (PD-L1) expression in small bowel adenocarcinomas (SBA)［J］.J Clin Oncol,2015,33(15): 3619-3619.
［35］Thota R, Gonzalez RS, Berlin J, et al. Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma ［J］? Am J Clin Pathol, 2017, 148(3):208-214.
［36］Xu C, Hua H, Chen T, et al. PD-L1 is correlated with p53 expression in patients with lung adenocarcinoma［J］. Int J Clin Exp Pathol, 2017,10(3):2701-2711.

[1]	ZHANG Wei, WANG Yingbin, CAO Lu, LIU Yan, ZHANG Li, LIU Jieting. Research progress of autophagy in intestinal ischemia-reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1061-1066.
[2]	ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang. Research progress of PARP inhibitors in pancreatic cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
[3]	YI Hong, GU Bing, CHEN Yunian, LI Huanan. Neutrophil extracellular traps and its role in gouty diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1167-1173.
[4]	QIAO Dawei, LI Yufang, XIAO Yun, JIANG Lishuang, BO Ping. Research progress of Scutellaria barbata against colorectal cancer and its metastasis mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 332-336.
[5]	DING Qiuhua, SHI Daohua. Advances on the molecular mechanism of metformin's antitumor effect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 350-354.
[6]	ZHANG Xue, WU Lan-xiang, ZHANG Tao-lan, WEN Chun-jie, FU Li-juan, ZHOU Hong-hao. Advances in multi-targeted anti-tumor mechanisms of β-phenethyl isothiocyanate [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 217-222.
[7]	HE Chun-hui, ZHAO Yi-qing, LI Xia, ZHOU Lu-yao. Research progress in molecular mechanism of the pharmacological actions of leonurine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(12): 1419-1423.
[8]	ZHANG Lin, LI Mao-lan, LI Song-gang, WU Wen-guang, LIU Ying-bin. Progress of the molecular mechanisms research of gallbladder cancer lymphatic metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(8): 919-923.
[9]	ZHAO Yin, LI Qin, ZHANG Xin-yue. Study progress of type I anaphylaxis reaction and anaphylactoid reaction on the basis of RBL-2H3 cell models [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(11): 1310-1314.